Sequenom Hammered by Market, Analysts | GenomeWeb

NEW YORK (GenomeWeb News) – The day after Sequenom's board of directors fired the firm's CEO and its senior VP of R&D, its shares tumbled 39 percent, and analysts who cover the firm noted a lack of clarity surrounding the investigation that led to the firing of those employees and surrounding the firm's technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.